Clinical Trials

LymphoidOther hematologic neoplasm

18 enrolled

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07221032 2026-04-14

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

12 enrolled

Multiple Myeloma

NCT06948084 2026-04-13

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

80 enrolled

Multiple Myeloma

NCT07485647 2026-03-20

Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

50 enrolled

Phase 3 Not yet recruiting

Multiple Myeloma

NCT07393282 2026-03-16

LINKER-SMM2

270 enrolled

Smoldering Multiple Myeloma, Multiple Myeloma

NCT07029776 2026-03-03

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

50 enrolled

Phase 2/3 Not yet recruiting

Multiple Myeloma

NCT07428369 2026-02-23

LINKER-MM8

1,570 enrolled

Multiple Myeloma

NCT07400744 2026-02-10

A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects

102 enrolled

Multiple Myeloma

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07335887 2026-01-13

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

39 enrolled

Phase 2/3 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

1,708 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07247097 2025-11-25

ELDORADO

160 enrolled

Multiple Myeloma

NCT06570915 2025-10-01

T-ALL-2024

LymphoidOther hematologic neoplasm

20 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07090954 2025-07-29

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

Phase 1/2 Not yet recruiting

32 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Multiple Myeloma

NCT07026604 2025-06-18

CCM-DS01

10 enrolled

CNS

Hemangioma, Cavernous, Central Nervous System

NCT07015021 2025-06-11

DKPD

Phase NA Not yet recruiting

72 enrolled

Multiple Myeloma

NCT06931704 2025-04-23

IFM 2024_06

176 enrolled

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT05581875 2022-10-17

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

48 enrolled

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05527340 2022-09-02

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

140 enrolled

Multiple Myeloma

NCT05054478 2021-09-23

PCL-2